Purpose of Review: This article discusses the recent advances in the diagnosis and treatment of Alzheimer disease (AD).
Recent Findings: In recent years, significant advances have been made in the fields of genetics, neuroimaging, clinical diagnosis, and staging of AD. One of the most important recent advances in AD is our ability to visualize amyloid pathology in the living human brain. The newly revised criteria for diagnosis of AD dementia embrace the use for biomarkers as supportive evidence for the underlying pathology. Guidelines for the responsible use of amyloid positron emission tomography (PET) have been developed, and the clinical and economic implications of amyloid PET imaging are actively being explored.
Summary: Our improved understanding of the clinical onset, progression, neuroimaging, pathologic features, genetics, and other risk factors for AD impacts the approaches to clinical diagnosis and future therapeutic interventions.
Address correspondence to Dr Liana G. Apostolova, Indiana Alzheimer’s Disease Center, 355 W 16th St, Suite 4700, Indianapolis, IN 46202, firstname.lastname@example.org.
Relationship Disclosure: Dr Apostolova serves as senior associate editor of Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring and receives personal compensation for serving on the speaker’s bureau of Eli Lilly and Company and GE Healthcare Worldwide. Dr Apostolova receives grant support from the Jim Easton Consortium for Alzheimer’s Drug Discovery and Biomarker Development and the National Institute on Aging.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Apostolova discusses the unlabeled/investigational use of antidepressant and antipsychotic medications for behavioral management as well as antidementia therapy in mild cognitive impairment.